Trinity Biotech plc disclosed that its next‑generation CGM+ continuous glucose monitoring system has achieved a significant reduction in mean absolute relative difference (MARD) during multi‑day wear, thanks to an updated electronics architecture. The new architecture also enables multimodal sensing and AI‑native analytics, allowing the device to capture additional physiological metrics such as heart activity, body temperature and physical activity alongside glucose. These technical gains are intended to support the company’s plan to initiate pivotal clinical trials in 2026 and to pursue regulatory submissions, positioning the CGM+ platform for entry into the $15 billion CGM market and adjacent digital health segments.
The CGM+ platform was unveiled in July 2025, and a needle‑free glucose sensor breakthrough was announced in August 2025. The March 10 announcement builds on those milestones by demonstrating a measurable improvement in accuracy and by adding multimodal sensing capabilities. The enhanced accuracy, measured by a lower MARD, brings the device closer to the industry’s accuracy standards, while the ability to record heart activity, temperature and activity data differentiates it from existing CGM products and expands its potential use cases in chronic disease management and consumer wellness.
CEO John Gillard said, “These are some of the most important technical advancements to date in our CGM+ development program. The glucose measurement accuracy gains achieved by the incorporation of key components of our enhanced electronics architecture gives us strong conviction to accelerate into pivotal trials this year. The fact that these enhanced electronic components also underpin our innovative multi‑modal sensing architecture gives us a valuable foundation from which we intend to deliver a truly differentiated device, CGM+, to key markets globally.” He added, “We are excited with what we have achieved, and we are increasingly confident that CGM+ provides Trinity Biotech with the platform to deliver a significant step‑change in the growth and scale of the company. We look forward to initiating a pivotal clinical trial and bringing this important solution to market.” Gillard also noted, “CGM+ is not just a device – it’s a proprietary data engine we are building for the AI health ecosystem. We believe this technology can power the next wave of personalized, predictive, and preventative care, while opening up entirely new commercial pathways for Trinity Biotech, from device sales to AI‑driven data services.”
The announcement signals a critical step toward regulatory approval and market entry. By meeting pivotal trial requirements in 2026, Trinity Biotech aims to secure FDA clearance and capture a share of the projected $15.3 billion global CGM market in 2026, with potential expansion into adjacent digital health segments. The company’s focus on a proprietary data engine also positions it to monetize data services beyond device sales, creating new revenue streams in the AI health ecosystem.
Financially, Trinity Biotech faces headwinds. Q4 2025 revenue is projected at $11.5 million to $12.5 million, down from $15.9 million in Q4 2024, largely due to disruptions in the global HIV testing market and manufacturing transition effects. The company has also secured a $25 million equity facility and is addressing Nasdaq listing deficiencies. While the CGM+ technical progress is promising, these financial challenges underscore the need for continued capital and operational efficiency to support the product’s commercial rollout.
The March 10 announcement marks a significant technical milestone for Trinity Biotech, but the company must navigate ongoing financial headwinds. Investors should weigh the potential market impact of the CGM+ platform against the current revenue decline, Nasdaq compliance issues, and the need for additional capital to support the product’s development and commercialization.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.